Justin "Jay" Bader, MD

2026

• AI-powered semantic segmentation model for enhanced ureteral mapping and real-time instrument feedback in robotic colorectal surgery

  . AI-powered semantic segmentation model for enhanced ureteral mapping and real-time instrument feedback in robotic colorectal surgery. Journal Of Robotic Surgery 2026, 20: 859. PMID: 42618847, DOI: 10.1007/s11701-026-03807-6.

  Peer-Reviewed Original Research

• Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma

  Bader JM, Dhiman A, Aguirre N, Ofori KA, Gupta P, Qin H, Sharma A, Mitchell O, Tjota MY, Husain AN, Drazer M, Churpek J, Kindler H, Turaga K. Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma. Npj Precision Oncology 2026 DOI: 10.1038/s41698-026-01495-x.

  Peer-Reviewed Original Research

  This study investigates the prognostic impact of somatic mutations in mesothelioma, showing NF2 truncating variants worsen survival, supporting genomic testing to guide treatment strategies.

  Full Summary

• Increased rates of surgical resection of early-stage small cell lung cancer in a single-institution cohort.

  Ely S, Bader JM, Udelsman BV, Zolfaghari EJ, Chiang AC, de Santis W, Reginauld S, Dhanasopon AP, Homer R, Cai G, Woodard GA. Increased rates of surgical resection of early-stage small cell lung cancer in a single-institution cohort. J Thorac Dis 2026, 18: 664. PMID: 42444860, DOI: 10.21037/jtd-2026-0460.

  Peer-Reviewed Original Research

• Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance

  Ofori K, Smart H, Liu S, Bader J, Aguirre N, Gupta P, Sharma A, Turaga K. Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance. Annals Of Surgical Oncology 2026, 1-4. PMID: 42265516, DOI: 10.1245/s10434-026-19903-8.

  Peer-Reviewed Original Research

  This study investigates the limitations of circulating tumor DNA (ctDNA) surveillance in stage II–III colon cancer, showing reduced detection of isolated peritoneal metastases due to biological constraints.

  Full Summary

• Natural history, treatment, survival, and causes of mortality in patients with subsolid and ground-glass nodules

  Bader J, Prince S, de Santis W, Kane E, Tanoue L, Bader A, Blasberg J, Detterbeck F, Woodard G. Natural history, treatment, survival, and causes of mortality in patients with subsolid and ground-glass nodules. Chest 2026 PMID: 42155700, DOI: 10.1016/j.chest.2026.04.053.

  Peer-Reviewed Original Research

  Altmetric

• Radiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer

  Bader J, Ermer T, de Santis W, Ragoowansi H, Kramer R, Zolfaghari E, Tremblay E, Resio B, Boffa D, Blasberg J, Bader A, Dacic S, Woodard G. Radiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer. JTCVS Open 2026, 101831. DOI: 10.1016/j.xjon.2026.101831.

  Peer-Reviewed Original Research

  Altmetric

• CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma

  Bader J, de Santis W, Kane E, Jaiswal A, Cho C, Kidacki M, Chen L, Dacic S, Woodard G. CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma. Translational Lung Cancer Research 2026, 15: 131-131. PMID: 42291360, PMCID: PMC13263804, DOI: 10.21037/tlcr-2026-1-0102.

  Peer-Reviewed Original Research

• Evolving therapeutics in colorectal cancer peritoneal metastases

  Bader J, Aguirre N, Schultz K, Ofori K, Godfrey E, Gupta P, Tseng R, Cecchini M, Sundar R, Turaga K. Evolving therapeutics in colorectal cancer peritoneal metastases. Cancer And Metastasis Reviews 2026, 45: 25. PMID: 42024175, DOI: 10.1007/s10555-026-10335-0.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  MeSH Keywords

• ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases

  Gupta P, Godfrey E, Schultz K, Qiao L, Aguirre N, Bader J, Foote M, Shen J, Shergill A, Cecchini M, Sundar R, Sheltzer J, Turaga K. ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases. Annals Of Surgical Oncology 2026, 33: 6194-6195. PMID: 41896510, DOI: 10.1245/s10434-026-19312-x.

  Peer-Reviewed Original Research

• ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases

  Gupta P, Godfrey E, Schultz K, Qiao L, Aguirre N, Bader J, Foote M, Shen J, Shergill A, Cecchini M, Sundar R, Turaga K. ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. Annals Of Surgical Oncology 2026, 33: 6200-6201. PMID: 41735726, DOI: 10.1245/s10434-026-19269-x.

  Peer-Reviewed Original Research

  This study investigates how molecular subtyping of colorectal cancer peritoneal metastases can guide personalized chemotherapy selection, finding CMS4 tumors respond better to mitomycin C and irinotecan.

  Full Summary